Evidence map›Paper›PMID 25961775›Full record

Trial reportBone marrow transplantation2015

Risk factors and timing of relapse after allogeneic transplantation in pediatric ALL: for whom and when should interventions be tested?

M A Pulsipher, B Langholz, D A Wall, K R Schultz, N Bunin, W Carroll, E Raetz, S Gardner, R K Goyal, J Gastier-Foster and 3 more

Open access · greenAbstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
7.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 70 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Factors Associated with Long-Term Risk of Relapse after Unrelated Cord Blood Transplantation in Children with Acute Lymphoblastic Leukemia in Remission.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2017
    Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Stem cell transplantation for ALL: you've always got a donor, why not always use it?Hematology. American Society of Hematology. Education Program · 2023
    Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Long non-coding RNA signatures and related signaling pathway in T-cell acute lymphoblastic leukemia.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022
    Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 10 institutions in 2 countries.

M A PulsipherDivision of Hematology and Hematological Malignancies, Huntsman Cancer Institute/University of Utah School of Medicine, Primary Children's Hospital, Salt Lake City, UT, USA.
B LangholzDepartment of Preventive Medicine, USC Keck School of Medicine, Los Angeles, CA, USA.
D A WallManitoba Blood and Marrow Transplant Program, Winnepeg, Manitoba, Canada.
K R SchultzDepartment of Pediatrics University of BC, BC Children's Hospital, Vancouver, British Columbia, Canada.
N BuninDivision of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
W CarrollNYU Department of Pediatrics and Cancer Institute, NYU Langone Medical Center, New York, NY, USA.
E RaetzDivision of Hematology and Hematological Malignancies, Huntsman Cancer Institute/University of Utah School of Medicine, Primary Children's Hospital, Salt Lake City, UT, USA.
S GardnerNYU Department of Pediatrics and Cancer Institute, NYU Langone Medical Center, New York, NY, USA.
R K GoyalDivision of Blood and Marrow Transplantation and Cellular Therapies, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
J Gastier-FosterDepartment of Pathology and Laboratory Medicine, Nationwide Children's Hospital, Columbus, OH, USA.
M BorowitzDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
D TeacheyDivision of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
S A GruppDivision of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Children's Hospital of Philadelphia · USNYU Langone Health · USBritish Columbia Children's Hospital · CAHuntsman Cancer Institute · USJohns Hopkins University · USKeck Hospital of USC · USNationwide Children's Hospital · USResearch Manitoba · CAUniversity of Pittsburgh Medical Center · USUniversity of Utah · US

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
COG FOREIGN ACCRUALU10CA098543 · NCI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI ADAMSON, PETER C. · 2003 to 2013
$335.5M
COG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8M
Children's Oncology Group Statistics &Data Center GrantU10CA098413 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI ANDERSON, JAMES R · 2003 to 2013
$67.5M
Pediatric Blood and Marrow Transplant ConsortiumU01HL069254 · NHLBI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI PULSIPHER, MICHAEL A · 2001 to 2010
$2.0M
Re-Engineering the Clinical Research EnterpriseN01HC045220 · HC · NATIONAL CHILDHOOD CANCER FOUNDATION · PI REAMAN, GREGORY H · 2004 to 2004
–
ONTOGENY OF AIRWAY SMOOTH MUSCLE FUNCTIONR29HL045220 · NHLBI · KAPI'OLANI MEDICAL CENTER/WOMEN/CHILDRN · PI NAKAMURA, KENNETH T · 1990 to 1994
–
NCI NIH HHS R01CA1116660NCI NIH HHS U10 CA098413NCI NIH HHS U10 CA098543NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180899NHLBI NIH HHS 2U01HL069254NHLBI NIH HHS N01 HC045220NHLBI NIH HHS N01 HC-45220/HHSN268200425220CNHLBI NIH HHS U01 HL069254
6 · The paper itself

Abstract

We previously showed that minimal residual disease (MRD) detection pre-hematopoietic cell transplant (HCT) and acute GvHD (aGvHD) independently predicted risk of relapse in pediatric ALL. In this study we further define risk by assessing timing of relapse and the effects of leukemia risk category and post-HCT MRD. By multivariate analysis, pre-HCT MRD <0.1% and aGvHD by day +55 were associated with decreased relapse and improved event-free survival (EFS). Intermediate leukemia risk status predicted decreased relapse, and improved EFS and overall survival (OS). Patients with pre-HCT MRD ⩾0.1% who did not develop aGvHD compared with those with MRD <0.1% who did develop aGvHD had much worse survival (2 years EFS 18% vs 71%; P=0.001, 2 years OS 46 vs 74%; P=0.04). Patients with pre-HCT MRD <0.1% who did not experience aGvHD had higher rates of relapse than those who did develop aGvHD (40% vs 13%; P= 0.008). Post-HCT MRD led to a substantial increase in relapse risk (HR=4.5, P<0.01). Patients at high risk of relapse can be defined after transplant using leukemia risk category, presence of MRD pre or post HCT, and occurrence of aGvHD. An optimal window to initiate intervention to prevent relapse occurs between day +55 and +200 after HCT.

Indexed as

Hematopoietic Stem Cell TransplantationPrecursor Cell Lymphoblastic Leukemia-LymphomaAcute DiseaseAdolescentAdultAllograftsChildChild, PreschoolDisease-Free SurvivalFemaleGraft vs Host DiseaseHumansInfantMaleNeoplasm, ResidualRecurrence

Identifiers

PMID25961775
PMCPMC4573663
OpenAlexW1481061448

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.